Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 4/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.41 |
| ▸ | ITGAV | P06756 | 8/20 | 0.41 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 6/20 | 0.40 |
| ▸ | ITGA5 | P08648 | 6/20 | 0.40 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20971411 | 0.84 | APP (0.47) | APPPDE10AHSD11B1KCNH2SCN5A | |
| SCHEMBL7797589 | 0.82 | APP (0.54) | APPPDE10AKCNH2SCN5AITGB3 | |
| SCHEMBL13626475 | 0.81 | HSD11B1 (0.42) | APPPDE10AHSD11B1KCNH2NPSR1 | |
| SCHEMBL7040754 | 0.81 | KCNH2 (0.46) | APPHSD11B1KCNH2SCN5ANPSR1 | |
| SCHEMBL6220219 | 0.81 | APP (0.53) | APPPDE10AKCNH2SCN5AITGB3 | |
| SCHEMBL1815740 | 0.81 | APP (0.53) | APPPDE10AKCNH2SCN5AITGB3 | |
| SCHEMBL23455586 | 0.79 | ITGB3 (0.54) | APPPDE10AITGB3ITGAVITGB6 | |
| SCHEMBL30073942 | 0.79 | ITGB3 (0.54) | APPPDE10AITGB3ITGAVITGB6 | |
| SCHEMBL4273309 | 0.79 | KCNH2 (0.52) | HSD11B1KCNH2NPSR1 | |
| SCHEMBL30336032 | 0.78 | APP (0.55) | APPPDE10AKCNH2SCN5AITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210069337-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2021-03-11 | — | — | US | disclosed |
| US-9701635-B2 | C-H fluorination of heterocycles with silver (II) fluoride | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-07-11 | — | — | US | disclosed |
| US-9701635-B2 | C-H fluorination of heterocycles with silver (II) fluoride | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160185723-A1 | C-H FLUORINATION OF HETEROCYCLES WITH SILVER (II) FLUORIDE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-30 | — | — | US | disclosed |
| US-20160185723-A1 | C-H FLUORINATION OF HETEROCYCLES WITH SILVER (II) FLUORIDE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-30 | — | — | US | disclosed |
| WO-2015013715-A2 | C-H FLUORINATION OF HETEROCYCLES WITH SILVER (II) FLUORIDE | THR REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-01-29 | — | — | WO | disclosed |
| WO-2015013715-A2 | C-H FLUORINATION OF HETEROCYCLES WITH SILVER (II) FLUORIDE | THR REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-01-29 | — | — | WO | disclosed |
| EP-1425010-B8 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | JANSSEN PHARMACEUTICALS INC (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-1425010-B1 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2011-10-26 | — | — | EP | disclosed |
| EP-1425010-A4 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-1061921-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-27 | — | — | EP | disclosed |
| EP-1025090-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2000-11-08 | — | — | EP | disclosed |
| EP-1025090-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2000-08-09 | — | — | EP | disclosed |
| CN-1238689-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1999-12-15 | — | — | CN | disclosed |
| EP-0957917-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-24 | — | — | EP | disclosed |
| EP-0946180-A1 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999045927-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999015508-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-01 | — | — | WO | disclosed |
| WO-1998015278-A1 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-16 | — | — | WO | disclosed |
| WO-1998014192-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185723-A1 | C-H FLUORINATION OF HETEROCYCLES WITH SILVER (II) FLUORIDE | AFF2, INF2, NPFFR2 | APP 2818/4885PDE10A 4438/4885HSD11B1 3763/4885 |
| US-20210069337-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | ITGAV, ITGA5, ITGB5 | APP 4034/4885PDE10A 4639/4885HSD11B1 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.